Skip to main content
Have a personal or library account? Click to login
Antineoplastic DNA-Binding Compounds: Intercalating and Minor Groove Binding Drugs Cover

Antineoplastic DNA-Binding Compounds: Intercalating and Minor Groove Binding Drugs

Archives of Industrial Hygiene and Toxicology
Volume 64 (2013): Issue 4 (December 2013)
By: ,  ,   and    
Open Access
|Dec 2013
References

References

  1. 1. Turner PR, Denny WA. The mutagenic properties of DNA minor-groove binding ligands. Mutat Res 1996;355:141-69. PMID: 8781582
    Open DOISearch in Google Scholar
  2. 2. Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Therap 2009;121:29-40. doi: 10.1016/j. pharmthera.2008.09.005
    Search in Google Scholar
  3. 3. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007;70:461-77. doi: 10.1021/np068054v
    Open DOISearch in Google Scholar
  4. 4. Hamilton PL, Arya DP. Natural product DNA major groove binders. Nat Prod Rep 2012;29:134-43. doi: 10.1039/ c1np00054c
    Open DOISearch in Google Scholar
  5. 5. Dervan PB. Molecular recognition of DNA by small molecules. Bioorg Med Chem 2001;9:2215-35. doi: 10.1016/ S0968-0896(01)00262-0
    Open DOISearch in Google Scholar
  6. 6. Wasselbourg S, Lauber K. Mechanisms of anticancer drug action. In: Los M, Gibson SB, editors. Apoptotic pathways as targets for novel therapies in cancer and other diseases. New York (NY): Springer Science Business Media, Inc.; 2005. p. 31-55.
    Open DOISearch in Google Scholar
  7. 7. Hoti N, Ma J, Tabassum S, Wang Y, Wu M. Triphenyl tin benzimidazolethiol, a novel antitumor agent, induces mitochondrial-mediated apoptosis in human cervical cancer cellssuppression of HPV-18 Encoded E6. J Biochem 2003;134:521-8. PMID: 14607978
    Open DOISearch in Google Scholar
  8. 8. Liu J, Campen A, Huang S, Peng S,Ye X, Palakal M, Dunker KA, Xia Y, Li S. Identifi cation of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profi ling data. BMC Med Genomics 2008;1:39-51. doi: 10.1186/1755-8794-1-39
    Open DOISearch in Google Scholar
  9. 9. Haq I. Thermodynamics of drug-DNA interactions. Arch Biochem Biophys 2002;15:1-15. PMID: 12061796
    Open DOISearch in Google Scholar
  10. 10. Gurova K. New hopes for old drugs: revising DNA-binding small molecules as anticancer agents. Future Oncol 2009;5:1685-704. doi: 10.2217/fon.09.127
    Open DOISearch in Google Scholar
  11. 11. Leal JFM, Martinez-Diez M, Garcia-Hernandez V, Moneo V, Domingo A, Bueren-Calabuig JA, Negri A, Gago F, Guillen-Navarro MJ, Aviles P, Cuevas C, Garcia-Fernandez LF, Galmarini CM. PMO1183, a new DNA minor groove covalent binder with potentandanti-tumour activity. Br J Pharmacol 2010;161:1099-110. doi: 10.1111/ j.1476-5381.2010.00945.x
    Open DOISearch in Google Scholar
  12. 12. Tidwell RR, Boykin DW. Dicationic DNA minor groove binders as antimicrobial agents. In: Demeunynck M, Bailly C, Wilson WD, editors. DNA and RNA binders: from small molecules to drugs. Vol. 2. Weinheim: Wiley-VCH; 2003. p. 414-60.
    Open DOISearch in Google Scholar
  13. 13. Xi H, Davis E, Ranjan N, Xue L, Hyde-Volpe D, Arya DP. Thermodynamics of nucleic acid “shape readout” by an aminosugar. Biochemistry 2011;50:9088-113. doi: 10.1021/ bi201077h
    Open DOISearch in Google Scholar
  14. 14. Kumar S, Xue L, Arya DP. Neomycin-neomycin dimer: an all-carbohydrate scaffold with high affi nity for AT-rich DNA duplexes. J Am Chem Soc 2011;133:7361-75. doi: 10.1021/ ja108118v
    Open DOISearch in Google Scholar
  15. 15. Zhang X, Zhang SC, Sun D, Hu J, Wali A, Pass H, Fernandez- Madrid F, Harbut MR, Tang N. New insight into the molecular mechanism of the biological effect of DNA minor groove binders. PLoS One. 2011;6:e25822. doi: 10.1371/ journal.pone.0025822
    Open DOISearch in Google Scholar
  16. 16. Avendano C, Menendez CJ. DNA Intercalators and topoisomerase inhibitors. In: Avendano C, Menendez JC, editors. Medicinal chemistry of anticancer drugs. Oxford: Elesevier BV; 2008. p. 199-228.
    Open DOISearch in Google Scholar
  17. 17. Milano A, Perri F, Ciarmiello A, Caponigro F. Targetedtherapy and imaging response: a new paradigm for clinical evaluation? Rev Recent Clin Trials 2011;6:259-65. PMID: 21682675
    Open DOISearch in Google Scholar
  18. 18. Marverti G, Cusumano M, Ligabue A, Di Pietro ML, Vainiglia PA, Ferrari A, Bergomi M, Moruzzi MS, Frassineti C. Studies on the anti-proliferative effects of novel DNAintercalating bipyridyl-thiourea-Pt(II) complexes against cisplatin-sensitive and -resistant human ovarian cancer cells. J Inorg Biochem 2008;102:699-712. PMID: 18082268
    Open DOISearch in Google Scholar
  19. 19. Martinez R, Chacon-Garcia L. The Search of DNAintercalators as antitumoral drugs: what it worked and what did not work. Curr Med Chem 2005;12:127-51. PMID: 15638732
    Open DOISearch in Google Scholar
  20. 20. Raj AS, Heddle JA. Simultaneous detection of chromosomal aberrations and sister-chromatid exchanges: experience with DNA intercalating agents. Mutat Res 1980;78:253-60. PMID: 7432360
    Open DOISearch in Google Scholar
  21. 21. Wilson WR, Harris NM, Ferguson LR. Comparison of the mutagenic and clastogenic activity of amsacrine and other DNA-intercalating drugs in cultured V79 Chinese hamster cells. Cancer Res 1984;44:4420-31. PMID: 6547875
    Search in Google Scholar
  22. 22. Palchaudhuri R, Hergenrother PJ. DNA as a target for anticancer compounds: methods to determine the mode of binding and the mechanism of action. Curr Opin Biotechnol 2007;18:497-503. doi: 10.1016/j.copbio.2007.09.006
    Open DOISearch in Google Scholar
  23. 23. Terakawa T, Miyake H, Muramaki M, Takenaka A, Fujisawa M. Salvage chemotherapy with methotrexate, etoposide and actinomycin D in men with metastatic nonseminomatous germ cell tumors with a choriocarcinoma component: a preliminary report. Int J Urol 2010;17:881-5. doi: 10.1111/ j.1442-2042.2010.02618.x
    Open DOISearch in Google Scholar
  24. 24. Milano A, Apice G, Ferrari E, Fazioli F, de Rosa V, de Luna AS, Laffaioli RV, Caponigro F. New emerging drugs in soft tissue sarcoma. Crit Rev Oncol Hematol 2006;59:74-84. PMID: 16533604
    Open DOISearch in Google Scholar
  25. 25. Schaich M, Illmer T, Aulitzky W, Bodenstein H, Clemens M, Neubauer A, Repp R, Schakel U, Soucek S, Wandt H, Ehninger G. Intensifi ed double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years. Haematologica 2002;87:808-15. PMID: 12161356
    Search in Google Scholar
  26. 26. Fiocchi SC, Selting KA, Rosenberg MP, Kolli P, Lenaz G, Henry C. An open-label, dose-escalating phase I study of elsamitrucin (SPI 28090) in treatment of malignant solid tumors in dogs. J Vet Intern Med 2011;25:897-902. doi: 10.1111/j.1939-1676.2011.0752.x
    Open DOISearch in Google Scholar
  27. 27. He Y, Zhang L, Song C. Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modifi ed with PEGylated liposomes. Int J Nanomedicine 2010;5697-705. PMID: 20957221
    Open DOISearch in Google Scholar
  28. 28. Mocellin S, Rossi CR, Brandes A, Nitti D. Adult soft tissue sarcomas: Conventional therapies and molecularly targeted approaches. Cancer Treat Rev 2006;32:9-27. PMID: 16338075
    Open DOISearch in Google Scholar
  29. 29. Salas JA, Mendez C. Indolocarbazole antitumour compounds by combinatorial biosynthesis. Curr Opin Chem Biol 2009;13:152-60. doi: 10.1016/j.cbpa.2009.02.003
    Open DOISearch in Google Scholar
  30. 30. Facompre M, Baldeyrou B, Bailly C, Anizon F, Marminon C, Prudhomme M, Colson P, Houssier C. DNA targeting of two new antitumour rebeccamycin derivatives. Eur J Med Chem 2002;37:925-32. PMID: 12660017
    Open DOISearch in Google Scholar
  31. 31. Bailly C, Qu X, Anizon F, Prudhomme M, Ois Riou J, Chaires JB. Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino sugar residue. Mol Pharmacol 1999;55:377-85. PMID: 9927631
    Open DOISearch in Google Scholar
  32. 32. Sanchez C, Salas AP, Brana AF, Palomino M, Pineda-Lucena A, Carbajo RJ, Mendez C, Moris F, Salas JA. Generation of potent and selective kinase inhibitors by combinatorial biosynthesis of glycosylated Indolocarbazoles. Chem Commun 2009;27:4118-20. doi: 10.1039/b905068j
    Open DOISearch in Google Scholar
  33. 33. Sanchez C, Zhu L, Brana AF, Salas AP, Rohr J, Mendez C, Salas JA. Combinatorial biosynthesis of antitumor indolocarbazole compounds. PNAS 2005;102:461-6. doi: 10.1073/pnas.0407809102
    Open DOISearch in Google Scholar
  34. 34. Gamage SA, Spicer JA, Finlay GJ, Stewart AJ, Charlton P, Baguley BC, Denny WA. Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs. J Med Chem 2001;44:1407-15. PMID: 11311063
    Open DOISearch in Google Scholar
  35. 35. Sappal DS, McClendon KA, Fleming JA, Thoroddsen V, Connolly K, Reimer C, Blackman RK, Bulawa CE, Osheroff N, Charlton P, Rudolph-Owen LA. Biological characterization of MLN944: A potent DNA binding agent. Mol Cancer Ther 2003;3:47-58. PMID: 14749475
    Open DOISearch in Google Scholar
  36. 36. Fujimoto S. Promising antitumor activity of a novel quinoline derivative, TAS-103, against fresh clinical specimens of eight types of tumors measured by fl ow cytometric DNA analysis. Biol Pharm Bull 2007;30:1923-9. PMID: 17917263
    Open DOISearch in Google Scholar
  37. 37. Bailly C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem 2000;7:39-58. PMID: 10637356
    Open DOISearch in Google Scholar
  38. 38. Baguley BC, Kerr DJ. Anticancer Drug Development. San Diego (CA): Academic Press; 2001.
    Search in Google Scholar
  39. 39. Varvaresou A, Iakovou K. Molecular modeling study of intercalation complexes of tricyclic carboxamides with d(CCGGCGCCGG)2 and d(CGCGAATTCGCG)2. J Mol Model 2010;17:2041-50. doi: 10.1007/s00894-010-0891-5
    Open DOISearch in Google Scholar
  40. 40. Williamson NR, Chawrai S, Leeper FJ, Salmond GPC. Prodiginines and their potential utility as proapoptotic anticancer agents. In: Fialho A, Chakrabarty A, editors. Emerging cancer therapy: microbial approaches and biotechnological tools. Hoboken (NJ): John Wiley & Sons; 2010. p. 333-66.
    Open DOISearch in Google Scholar
  41. 41. Manderville RA. Synthesis, proton-affi nity and anti-cancer properties of the prodigiosin-group natural products. Curr Med Chem Anticancer Agents 2001;1:195-218. PMID: 12678767
    Open DOISearch in Google Scholar
  42. 42. Bernardes N, Seruca R, Chakrabarty AM, Fialho AM. Microbial-based therapy of cancer. Bioeng Bugs 2010;1:178-90. doi: 10.4161/bbug.1.3.10903
    Open DOISearch in Google Scholar
  43. 43. Chawrai SR, Williamson NR, Salmond GPC, Leeper FJ. Chemoenzymatic synthesis of prodigiosin analoguesexploring the substrate specifi city of PigC. Chem Commun 2008;16:1862-4. doi: 10.1039/B719353J
    Open DOISearch in Google Scholar
  44. 44. Cancerquest. Doxorubicin [displayed 9 June 2013]. Available at http://www.cancerquest.org/drugs/doxorubicin
    Search in Google Scholar
  45. 45. Jakubowiak AJ, Kendall T, Al-Zoubi A, Khaled Y, Mineishi S, Ahmed A, Campagnaro E, Brozo C, Braun T, Talpaz M, Kaminski MS. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol 2009;27:5015-22. doi: 10.1200/ JCO.2008.19.5370
    Open DOISearch in Google Scholar
  46. 46. Plosker GL, Faulds D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 1993;45:788-856. PMID: 7686469
    Open DOISearch in Google Scholar
  47. 47. The Scott Hamilton CARES Initiative. Mitoxantrone [displayed 9 June 2013]. Available at http://www.chemocare.com/bio/mitoxantrone.asp
    Search in Google Scholar
  48. 48. Yamori T, Matsunaga A, Sato S, Yamazaki K, Komi A, Ishizu K, Mita I, Edatsugi H, Matsuba Y, Takezawa K, Nakanishi O, Hiroshi Kohno H, Nakajima Y, Komatsu H, Andoh T, Tsuruo T. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by anandhuman cancer cell line panel. Cancer Res 1999;59:4042-9. PMID: 10463605
    Search in Google Scholar
  49. 49. David-Cordonnier MH, Hildebrand MP, Baldeyrou B, Lansiaux A, Keuser C, Benzschawel K, Lemster T, Pindur U. Design, synthesis and biological evaluation of new oligopyrrole carboxamides linked with tricyclic DNAintercalators as potential DNA ligands or topoisomerase inhibitors. Eur J Med Chem 2007;42:752-71. PMID: 17433851
    Open DOISearch in Google Scholar
  50. 50. Bhuyan BK, Newell KA, Crampton SL, Von Hoff DD. CC-1065 (NSC 298223), a most potent antitumor agent: kinetics of inhibition of growth, DMA synthesis, and cell survival. Cancer Res 1982;42:3532-7. PMID: 7105029
    Search in Google Scholar
  51. 51. Wanga X, Chub N, Wanga N, Chao Liua Q, Jianga C, Wanga X, Ikejima T, Chenga M. Newly synthesized bis-benzimidazole derivatives exerting anti-tumor activity through induction of apoptosis and autophagy. Bioorg Med Chem Lett 2012;22:6297-300. doi: 10.1016/j.bmcl.2012.06.102
    Open DOISearch in Google Scholar
  52. 52. Hirota M, Fujiwara T, Mineshita S, Sugiyama H, Teraoka H. Distamycin A enhances the cytotoxicity of duocarmycin A and suppresses duocarmycin A-induced apoptosis in human lung carcinoma cells. Int J Biochem Cell Biol 2007;39:988-96. doi: 10.1016/j.biocel.2007.01.019
    Open DOISearch in Google Scholar
  53. 53. Bielawski K, Wolczynski S, Bielawska A. DNA-binding properties and cytotoxicity of extended aromatic bisamidines in breast cancer MCF-7 cells. Pol J Pharmacol 2001;53:143-7. PMID: 11787954
    Open DOISearch in Google Scholar
  54. 54. Yang YH, Cheng MS, Wang QH, Nie H, Liao N, Wang J, Chen H. Design, synthesis, and anti-tumor evaluation of novel symmetrical bis-benzimidazoles. Eur J Med Chem 2009;44:1808-12. doi: 10.1016/j.ejmech.2008.07.021
    Open DOISearch in Google Scholar
  55. 55. Chen AY, Yu C, Bodley A, Peng LF, Liu LF. A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. Cancer Res 1993;53:1332-7. PMID: 8383008
    Search in Google Scholar
  56. 56. Pilch DS, Xu Z, Sun Q, Lavoie EJ, Liu LF, Breslauer KJ. A terbenzimidazole that preferentially binds and conformationally alters structurally distinct DNA duplex domains: A potential mechanism for topoisomerase I poisoning. Proc Natl Acad Sci USA 1997;94:13565-70.
    Open DOISearch in Google Scholar
  57. 57. Bailly C, Chessaro G, Carrasco C, Joubert A, Mann J, Wilson WD, Neidle S. Sequence-specifi c minor groove binding by bis-benzimidazoles: water molecules in ligand recognition. Nucleic Acids Res 2003;31:1514-24. PMID: 12595560
    Open DOISearch in Google Scholar
  58. 58. Vekshin N. Binding of Hoechst with nucleic acids using fl uorescence spectroscopy. J Biophys Chem 2011;2:443-7. doi: 10.4236/jbpc.2011.24052
    Open DOISearch in Google Scholar
  59. 59. Invitrogen. Hoechst Stains [displayed 9 June 2013]. Available at http://probes.invitrogen.com/media/pis/mp21486.pdf
    Search in Google Scholar
  60. 60. Leitner F, Paillasson S, Ronot X, Demongeot J. Dynamic functional and structural analysis of living cells: new tools for vital staining of nuclear DNA and for characterisation of cell motion. Acta Biotheor 1995;43:299-317. PMID: 8919346
    Open DOISearch in Google Scholar
  61. 61. Chen AY, Yu C, Gatto B, Liu LF. DNA minor groove-binding ligands: A different class of mammalian DNA topoisomerase I inhibitors. Proc Natl Acad Sci USA 1993;90:8131-5. doi: 10.1073/pnas.90.17.8131
    Open DOISearch in Google Scholar
  62. 62. Baraldi PG, Cacciari B, Guiotto A, Romagnoli R, Zaid AN, Spalluto G. DNA minor-groove binders: results and design of new antitumor agents. Il Farmaco 1999;54:15-25. doi: 10.1016/S0014-827X(98)00102-5
    Open DOISearch in Google Scholar
  63. 63. Kamal A, Reddy PS, Reddy DR, Laxman E. DNA binding potential and cytotoxicity of newly designed pyrrolobenzodiazepine dimers linked through a piperazine side-armed-alkane spacer. Bioorg Med Chem 2006;14:385-94. PMID: 16185884
    Open DOISearch in Google Scholar
  64. 64. ClinicalTrails.gov. SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia [displayed 9 June 2013]. Available at http://clinicaltrials.gov/ct2/show/NCT00301769
    Search in Google Scholar
  65. 65. Baron RM, Lopez-Guzman S, Riascos DF, Macias AA, Layne MD, Cheng G, Harris C, Chung SW, Reeves R, von Andrian UH, Perrella MA. Distamycin A inhibits HMGA1-binding to the P-selectin promoter and attenuates lung and liver inflammation during murine endotoxemia. PLoS One 2010;5:e10656. doi: 10.1371/journal.pone.0010656
    Open DOISearch in Google Scholar
  66. 66. Nelson SM, Ferguson LR, Denny WA. Non-covalent ligand/ DNA interactions: Minor groove binding agents. Mutat Res 2007;623:24-40. PMID: 17507044
    Open DOISearch in Google Scholar
  67. 67. Cortesi R, Romagnoli R, Drechsler M, Menegatti E, Zaid AN, Ravani L, Esposito E. Liposomes- and ethosomesassociated distamycins: as comparative study. J Liposome Res 2009;20:277-85. doi: 10.3109/08982100903443057
    Open DOISearch in Google Scholar
  68. 68. Cozzi P. A new class of cytotoxic DNA minor groove binders: alpha-halogenoacrylic derivatives of pyrrolecarbamoyl oligomers. Il Farmaco 2001;56:57-65. doi: 10.1016/S0014-827X(01)01009-6
    Open DOISearch in Google Scholar
  69. 69. Vialleta TBJ, Stewart D, Shepherdd F, Ayoubb J, Cormief Y, DiPietrof N, Stewardg W. Tallimustine is inactive in patients with previously treated small cell lung cancer. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Lung Cancer 1996;15:367-73. PMID: 8959681
    Open DOISearch in Google Scholar
  70. 70. Punt CJA, Humblet Y, Roca E, Dirix LJ, Wainstein R, Polli A, Corradino I. Tallimustine in advanced previously untreated colorectal cancer, a phase II study. Br J Cancer 1996;73:803-4. PMID: 8611384
    Open DOISearch in Google Scholar
  71. 71. Neidle S, Kelland LR, Trent JO, Simpson IJ, Boykin DW, Kumar A, Wilson WD. Cytotoxicity of bis(Phenylamidiniu m)furan alkyl derivatives in human tumour cell lines: realation to DNA minor groove binding. Bioorg Med Chem Lett 1997;7:1403-8. doi: 10.1016/S0960-894X(97)00229-1
    Open DOISearch in Google Scholar
  72. 72. Smith JA, Bifulco G, Case DA, Boger DL, Gomez-Paloma L, Chazin WJ. The Structural basis for in situ activation of DNA alkylation by duocarmycin. J Mol Biol 2000;300:1195-204. PMID: 10903864
    Open DOISearch in Google Scholar
  73. 73. Tietze LF, Schuster HJ, Schmuck K, Schuberth I, Alves F. Duocarmycin-based prodrugs for cancer prodrug monotherapy. Bioorg Med Chem 2008;16:6312-8. doi: 10.1016/j.bmc.2008.05.009 Mišković K, et al.Arh Hig Rada Toksikol 2013;64:593-602
    Search in Google Scholar
DOI: https://doi.org/10.2478/10004-1254-64-2013-2371 | Journal eISSN: 1848-6312 (formerly 0004-1254) | Journal ISSN: 0004-1254
Journal RSS Feed
Language: English, Croatian, Slovenian
Page range: 593 - 602
Published on: Dec 13, 2013
Published by: Institute for Medical Research and Occupational Health
In partnership with: Paradigm Publishing Services
Keywords:
chemotherapy,
DNA intercalator,
DNA minor groove binder,
organic compounds derivatives
Related subjects:
Medicine,
Basic medical science,
Basic medical science, other

© 2013 Katarina Mišković, Maro Bujak, Mirela Baus Lončar, Ljubica Glavaš-Obrovac, published by Institute for Medical Research and Occupational Health
This work is licensed under the Creative Commons License.

Volume 64 (2013): Issue 4 (December 2013)
Previous article
Next article